Brugada Syndrome Market Size was valued at USD 1.17 Billion in 2023. The Brugada Syndrome market industry is projected to grow from USD 1.24 Billion in 2024 to USD 1.95 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.75% during the forecast period (2024 - 2032).The high frequency of cardiac conditions like Brugada syndrome and others and the enormous need for detection and treatment techniques are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
In March 2022, Chulalongkorn University's Faculty of Medicine, along with 10 prominent institutes in Thailand, are actively seeking viable treatment methods for Brugada syndrome. Brugada syndrome is an inherited condition characterized by irregular heart rhythms and the potential for abrupt cardiac arrest. The illness was named after Spanish cardiologists Pedro and Josep Brugada, who documented it in 1992. Their brother Ramon was the first to identify the possible genetic basis in 1998. This illness has been identified in a significant number of Thai individuals, particularly those residing in the Northern and Northeastern regions. The National Research Council has provided financing to the university and 10 other institutions to conduct a study on 239 patients with the syndrome, as well as a control group of 478 individuals, utilizing genetic sequencing. The study identified a mutation in the SCN5A gene in 15% of the participants, although not all individuals are at risk of developing Brugada syndrome. Implantable cardioverter-defibrillators can effectively treat Brugada syndrome when detected promptly and accurately. The research council has allocated funds to sponsor a study investigating the efficacy of radiofrequency ablation in the treatment of Brugada syndrome.
Market CAGR for Brugada Syndrome is being driven by the rising prevalence. The increasing prevalence of cardiac diseases such as Brugada syndrome and others and critical demand for diagnostic and therapeutic techniques drive the market. The market for Brugada syndrome is also rising as diagnostic services for respiratory disorders become more widely available. Additionally, favorable reimbursement practices are anticipated to fuel the growth of the Brugada syndrome market. The main factor driving the industry is the lengthy waiting lists for cardiovascular transplants. Due to an increase in the frequency of heart failure, there has been a significant increase in the demand for heart transplants in recent years. Long waiting lists for cardiovascular transplants are the main factor driving the industry.
The need for heart transplants has greatly increased as heart failure has become more common. However, the inability to meet the present demand has resulted in a shortage of organs eligible for transplantation. There were about 4150 candidates on the heart transplant waiting list as of March 2022, according to the National Database of the Health Resources and Services Administration of the United States. Even nationally, there are notable differences in the number of volunteers and patients on waiting lists. For instance, only over 500 volunteers were available in Australia in 2022, even though over 1,760 individuals were waiting for heart transplants. The number of people on waiting lists for a heart transplant has increased by 120% since 2010, according to the Transplant Activity Report 2022.
The alarming rise in the prevalence of cardiac disorders is the major factor propelling the growth of the worldwide Brugada syndrome market. Additionally, the industry has benefited from the enormous need for treatment and diagnosis techniques. Additionally, a rise in the availability of diagnostic services for respiratory disorders has been seen, which has greatly propelled the market's expansion. Additionally, increased knowledge of these uncommon syndromes has made it possible for patients to receive the right medical care, which is a major contributor to the worldwide market expansion. Additionally, the industry is being driven forward by reimbursement plans provided by public and commercial insurance organizations in nations including the UK, Canada, Germany, and the US. The impact of Western culture on adults, lifestyle modifications, and smoking addiction are other elements that support the market's expansion. Environmental contamination and exposure to dangerous chemicals also contribute to the market's expansion. Brugada syndrome therapy is expensive, which restricts market expansion. Thus, driving the Brugada Syndrome market revenue.
Based on the diagnosis, the Brugada Syndrome market segmentation includes an electrocardiogram, electrophysiology (Ep) test, and genetic testing. The electrocardiogram segment dominated the market, accounting for 35% of market revenue. The heart's electrical impulses are quickly and painlessly recorded during an electrocardiogram (ECG). During an ECG, sensors (electrodes) are positioned on the chest and, occasionally, the limbs. The examination might find structural and rhythmic anomalies in the heart. This examination detects the electrical activity that propels your heartbeat. A doctor might do the test twice since a characteristic Brugada syndrome pattern might not appear immediately.
Based on treatment, the Brugada Syndrome market segmentation includes implantable cardioverter-defibrillator and drug therapy. The drug therapy segment dominated the market. Several medications' recent inventions and approval are to blame for this expansion. For instance, the Food and Drug Administration's CDE Research approved new drug therapies amid the unimaginable strain the coronavirus pandemic put on healthcare services, giving patients with a range of illnesses new hope for a better standard of living and, in some cases, better odds of surviving life-threatening illnesses. Several innovative medications have been approved for use in patients with rare illnesses.
Based on End Users, the Brugada Syndrome market segmentation includes hospitals & clinics and diagnostic centers. The hospitals & clinics generated the most income (70.4%). This sector includes conventional hospitals, mental health institutions, specialty hospitals, and substance abuse centers that treat and diagnose various illnesses. It also includes clinics that provide family planning advice, renal dialysis, and other outpatient care services.
Figure 1: Brugada Syndrome Market, by End User, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The Asia Pacific Brugada Syndrome market, will dominate this market. There is a significant need for diagnostic testing, and early detection and treatment of heart disease are receiving more attention. The market is growing due to lifestyle modifications, adult smokers' addictions, and the impact of Western society. Additionally, the market for Brugada syndrome is expanding due to rising environmental contamination and exposure to hazardous chemicals.
Hence, the major countries studied in the market report are The US, Canada, Japan, India, German, France, the UK, Italy, Spain, China, Australia, South Korea, and Brazil.
Figure 2: BRUGADA SYNDROME MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Brugada Syndrome market accounts for the second-largest market share an increased focus on heart disease diagnosis, including Brugada syndrome and others. Further, the German Brugada Syndrome market held the largest market share, and The European region's fastest-growing market was the UK Brugada Syndrome market.
The North America Brugada Syndrome Market is expected to grow fastest from 2023 to 2032. An increasing number of people are receiving heart-related diagnoses, and electrocardiograms and electrophysiology (EP) tests are being used more often to detect illnesses. The United States is also the largest market in North America due to a sizable number of market players producing medications for Brugada syndrome and growing awareness about risk factors and cases of the illness. Moreover, the US Brugada Syndrome market held the largest market share, and the Asia-Pacific region's fastest-growing market was the Canadian Brugada Syndrome market.
Brugada Syndrome Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Brugada Syndrome market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Brugada Syndrome industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Brugada Syndrome industry to serve clients and expand the market sector. The Brugada Syndrome industry has provided some of the most important benefits recently. Medtronic plc, Abbott Laboratories, and other major companies in the Brugada Syndrome market are aiming to enhance market demand by investing in research and development activities.
An American manufacturer of medical equipment is Medtronic plc. Although it operates largely in the United States, it also does business in more than 150 other nations and employs more than 90,000 people. It creates and produces medical treatments and technology. The Diabetes Group, the Restorative Therapies Group, the Cardiac and Vascular Group, and the Minimally Invasive Therapies Group are Medtronic's four primary business divisions. More than 30 chronic illnesses, including heart failure, Parkinson's disease, urine incontinence, Down syndrome, obesity, chronic pain, spinal abnormalities, and diabetes, are treated by the devices and therapies that Medtronic develops and produces. The primary medical disciplines of cardiac surgery, interventional cardiology, and vascular surgery are all covered by Medtronic's cardiovascular treatments. The medications are used to lessen the damaging effects of structural, aortic, and coronary heart disease.
Illinois serves as the corporate headquarters of Abbott Laboratories, an American healthcare and medical device company. In order to produce well-known pharmaceuticals, Chicago doctor Wallace Calvin Abbott founded the company in 1888; nowadays, it sells branded generic drugs, dietary supplements, medical equipment, and diagnostics. To house its division for research-based medications, it established AbbVie in 2013.Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip are among Abbott's products.Diagnostics, medical equipment, branded generic drugs, and nutritional goods comprise Abbott's core businesses, which have been expanded via acquisitions. Abbott, a pioneer in healthcare, enables people to live more fully at all phases of life. With top companies and products in diagnostics, medical equipment, nutrition, and branded generic medications, their portfolio of game-changing technology covers their 115,000 coworkers.
Key Companies in the Brugada Syndrome market include
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.17 Billion |
| Market Size 2024 | USD 1.24 Billion |
| Market Size 2032 | USD 1.95 Billion |
| Compound Annual Growth Rate (CAGR) | 5.75% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | GeneDx (U.S), PGxHealth LLC (U.S), Abbott (U.S), GE Healthcare (U.K), Medtronic (U.S.), Pfizer, Inc (U.S), Boston Scientific Corporation (U.S.), GlaxoSmithKline (U.K), Eli Lilly Company (U.S), Taj Pharmaceuticals Ltd (India), and others |
| Key Market Opportunities | Increasing availability of diagnostic services for respiratory illness |
| Key Market Dynamics | High prevalence of heart diseases |
Frequently Asked Questions (FAQ) :
The Brugada Syndrome market size was valued at USD 1.17 Billion in 2022.
The market is projected to grow at a CAGR of 5.75% during the forecast period, 2024-2032.
North America had the largest share in the market
The key players in the market are General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., The Coca-Cola Company.
The beverage category dominated the market in 2022.
The store based had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
